Literature DB >> 10631655

Biological markers in amyotrophic lateral sclerosis: help or hindrance?

W G Bradley1.   

Abstract

Biological markers play an important role in the development of the understanding of a disease, its diagnosis and treatment. This is particularly true of amyotrophic lateral sclerosis (ALS) at this time. We need better biological markers for the diagnosis, for improved understanding of the underlying pathogenetic mechanisms, and for assistance in new drug development. This review of currently available biological and surrogate markers in ALS discusses novel approaches to the use of such markers, and new drugs for the treatment of ALS.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10631655     DOI： 10.1007/bf03161084

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  5 in total

1.  Riluzole does not have an acute effect on motor thresholds and the intracortical excitability in amyotrophic lateral sclerosis.

Authors:  M Sommer; F Tergau; S Wischer; C D Reimers; W Beuche; W Paulus
Journal:  J Neurol       Date:  1999-11       Impact factor: 4.849

2.  Bipap improves survival and rate of pulmonary function decline in patients with ALS.

Authors:  K A Kleopa; M Sherman; B Neal; G J Romano; T Heiman-Patterson
Journal:  J Neurol Sci       Date:  1999-03-15       Impact factor: 3.181

3.  Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo.

Authors:  E P Pioro; J P Antel; N R Cashman; D L Arnold
Journal:  Neurology       Date:  1994-10       Impact factor: 9.910

4.  Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements.

Authors:  W Block; J Karitzky; F Träber; C Pohl; E Keller; R R Mundegar; R Lamerichs; H Rink; F Ries; H H Schild; F Jerusalem
Journal:  Arch Neurol       Date:  1998-07

5.  Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy.

Authors:  S Kalra; N R Cashman; A Genge; D L Arnold
Journal:  Neuroreport       Date:  1998-06-01       Impact factor: 1.837
  5 in total
  3 in total

1.  The vitamin D activator CYP27B1 is upregulated in muscle fibers in denervating disease and can track progression in amyotrophic lateral sclerosis.

Authors:  Ying Si; Mohamed Kazamel; Yuri Kwon; Ikjae Lee; Tina Anderson; Siyu Zhou; Marcas Bamman; Derek Wiggins; Thaddaeus Kwan; Peter H King
Journal:  J Steroid Biochem Mol Biol       Date:  2020-03-03       Impact factor: 4.292

Review 2.  Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis.

Authors:  Martin R Turner; Michael Benatar
Journal:  Muscle Nerve       Date:  2014-11-24       Impact factor: 3.217

3.  Wnt antagonist FRZB is a muscle biomarker of denervation atrophy in amyotrophic lateral sclerosis.

Authors:  Thaddaeus Kwan; Mohamed Kazamel; Kristina Thoenes; Ying Si; Nan Jiang; Peter H King
Journal:  Sci Rep       Date:  2020-10-07       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.